In support of this, the most prevalent drugs administered to AD patients that provide temporary symptomatic relief are acetylcholinesterase inhibitors (Selkoe, 1997; Kumar et al., 2015) that increase the life span of ambient ACh. This evidence concerns the gene ACHE and Alzheimer disease.